MannKind Corporation, a biopharmaceutical company, focuses on the development and commercialization of inhaled therapeutic products for diabetes and pulmonary arterial hypertension patients. It offers Afrezza, a dry powder formulation of human insulin that controls high blood sugar in adults with type 1 and type 2 diabetes in the United States. The company was founded in 1991 and is headquartered in Westlake Village, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [04/24/2018 21:00 PDT] Market Maker Surveillance Report. MNKD, Winning Stocks With Lowest Price Friction For Tuesday, April 24th 2018
• [04/12/2018 10:00 PDT] MannKind Corporation (NASDAQ:MNKD), Down By 5.92% ($0.10) From $1.690 After BUYINS.NET Report Predicted Stock Would Go Down Due To Bearish Conditions
• [04/10/2018 06:26 PDT] MNKD Expected to Trade Down After Bearish Patterns Develop